
|Articles|August 24, 2022
GNS and Servier Announce AI Collaboration
Advertisement
GNS and Servier announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).
The collaboration will address key questions about how MM progresses in different patient subpopulations. This work will initially leverage the GNS Gemini Digital Twin for MM developed using the rich clinico-genomic data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study.
Read more about the new partnership
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
3
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5




